CSIMarket
 


Painreform Ltd  (NASDAQ: PRFX)
Other Ticker:  
 

Painreform Ltd's Quick Ratio

PRFX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth

 


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2024, Quick Ratio deteriorated to 1.61 a new company low.

Within Major Pharmaceutical Preparations industry 313 other companies have achieved higher Quick Ratio than Painreform Ltd in fourth quarter 2024. While Quick Ratio total ranking in the fourth quarter 2024 has deteriorated compared to the prior quarter from 0 to 1283.

Explain Quick Ratio?
How much Cash & cash equivalents PRFX´s has?
What are PRFX´s Current Liabilities?


PRFX Quick Ratio (Dec 31 2024)
Q4
0
Q3
0
Q2
0
Q1
(Dec 31 2022)
Q4
Y / Y Current Liabilities Change 103.21 % 103.21 % 103.21 % 103.21 % 31.89 %
Y / Y Cash & cash equivalent Change -58.09 % -58.09 % -58.09 % -58.09 % -38.5 %
Quick Ratio MRQ 1.61 1.61 1.61 1.61 7.8
PRFX's Total Ranking # 1283 # 0 # 0 # 1301 #
Seq. Current Liabilities Change 0 % 0 % 0 % 103.21 % 0 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % -58.09 % 0 %



Quick Ratio fourth quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 314
Healthcare Sector # 558
Overall Market # 1283


Quick Ratio Statistics
High Average Low
16.72 8.71 1.61
(Dec 31 2021)   (Dec 31 2024)




Financial Statements
Painreform Ltd's Current Liabilities $ 3 Millions Visit PRFX's Balance sheet
Painreform Ltd's Cash & cash equivalent $ 4 Millions Visit PRFX's Balance sheet
Source of PRFX's Sales Visit PRFX's Sales by Geography


Cumulative Painreform Ltd's Quick Ratio

PRFX's Quick Ratio for the trailling 12 Months

PRFX Quick Ratio

(Dec 31 2024)
12 Months
0
12 Months
0
12 Months
0
12 Months
(Dec 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth 103.21 % 88.82 % 72.45 % 53.67 % 31.89 %
Y / Y Cash & cash equivalent TTM Growth -58.09 % -51.2 % -45.96 % -41.83 % -38.5 %
Quick Ratio TTM 1.61 2.48 3.65 5.3 7.8
Total Ranking TTM # 3502 # 0 # 0 # 2770 #
Seq. Current Liabilities TTM Growth 14.54 % 17.02 % 20.51 % 25.8 % 6.43 %
Seq. Cash & cash equivalent TTM Growth -25.73 % -20.47 % -16.99 % -14.52 % -13.53 %


  News about Painreform Ltd Quick Ratio

PainReform Secures $4 Million in Public Offering, Fueling Growth in Pharmaceutical Innovation

PainReform s Public Offering Signals Growth in Clinical-Stage Pharmaceutical Industry
In a recent announcement, PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company, unveiled the pricing of its public offering, marking a significant milestone for the company s growth. The offering includes 5,000,000 of PainReform s ordinary shares (or ordinary share equivalents) and warrants to purchase up to 5,000,000 ordinary shares, with a combined public offering price of $0.80 per share (or per ordinary share equivalent) and accompanying warrant.
The decision to go public with this offering is a strategic move by PainReform to secure necessary funding for their ongoing initiatives in the reformulation of established therapeutics. The proceeds from the offering will support the company s clinical trials and the development of novel treatments, aiming to address unmet medical needs in various therapeutic areas.

PainReform Secures $1.3 Million in Funding through Warrant Exercise, Accelerating Innovation in Drug Pipeline

PainReform Ltd Announces Exercise of Warrants, Garnering Approximately $1.3 Million in Gross Proceeds
TEL AVIV, Israel, Dec. 26, 2023 (GLOBE NEWSWIRE) PainReform Ltd (Nasdaq: PRFX), a leading clinical-stage specialty pharmaceutical company specializing in the reformulation of established therapeutics, has recently made a significant announcement. The company revealed the immediate exercise of certain outstanding warrants, enabling the purchase of up to 467,896 ordinary shares. These warrants were initially issued by PainReform in July 2023 and will now be exercised at a reduced price of $2.85 per ordinary share, as opposed to the original exercise price of $9.00 per share.
The ordinary shares acquired through the exercise of warrants are registered under an effective registration statement on Form F-1 (File No. 333-274220). The completion of this offering is expected to take place around December 29, 2023, subject to the fulfillment of customary closing conditions.


On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2024 to $2.66 millions, cumulative Quick Ratio decreased to 1.61 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 446 other companies have achieved higher Quick Ratio than Painreform Ltd. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2024 from 0 to 3502.

Explain Quick Ratio?
How much Cash & cash equivalents PRFX´s has?
What are PRFX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 447
Healthcare Sector # 914
Within the Market # 3502


trailing twelve months Quick Ratio Statistics
High Average Low
16.72 10.43 1.61
(Dec 31 2021)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Dec 31 2024, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2024 MRQ Cash & cash equivalentDec 31 2024 MRQ Current Liabilities
Enanta Pharmaceuticals Inc  4.42 $ 216.691  Millions$ 49.050  Millions
Bridgebio Pharma Inc   4.41 $ 681.101  Millions$ 154.400  Millions
Relmada Therapeutics Inc  4.36 $ 44.909  Millions$ 10.291  Millions
Uniqure N v   4.36 $ 158.930  Millions$ 36.452  Millions
Arcus Biosciences Inc   4.33 $ 978.000  Millions$ 226.000  Millions
Catalyst Pharmaceuticals Inc   4.29 $ 517.553  Millions$ 120.678  Millions
Lava Therapeutics Nv  4.25 $ 76.576  Millions$ 18.006  Millions
Veru Inc   4.19 $ 26.607  Millions$ 6.348  Millions
Vyne Therapeutics Inc   4.18 $ 61.516  Millions$ 14.720  Millions
Xoma Royalty Corporation  4.17 $ 101.654  Millions$ 24.374  Millions
Nektar Therapeutics  4.16 $ 255.226  Millions$ 61.400  Millions
Cryoport inc   4.10 $ 264.651  Millions$ 64.563  Millions
Mira Pharmaceuticals Inc   3.92 $ 2.833  Millions$ 0.723  Millions
Can Fite Biopharma Ltd  3.84 $ 7.887  Millions$ 2.052  Millions
Adial Pharmaceuticals Inc  3.84 $ 3.751  Millions$ 0.976  Millions
Matinas Biopharma Holdings Inc   3.83 $ 7.284  Millions$ 1.900  Millions
Renovorx Inc   3.75 $ 7.154  Millions$ 1.909  Millions
Equillium Inc   3.67 $ 22.575  Millions$ 6.159  Millions
Foghorn Therapeutics Inc   3.64 $ 243.747  Millions$ 66.989  Millions
Arcturus Therapeutics Holdings Inc   3.62 $ 237.028  Millions$ 65.489  Millions
Aclaris Therapeutics Inc   3.60 $ 113.594  Millions$ 31.596  Millions
Lipella Pharmaceuticals Inc   3.49 $ 2.185  Millions$ 0.626  Millions
Phathom Pharmaceuticals Inc   3.47 $ 297.263  Millions$ 85.728  Millions
Tg Therapeutics Inc   3.43 $ 311.000  Millions$ 90.679  Millions
Leap Therapeutics Inc   3.42 $ 47.249  Millions$ 13.810  Millions
Revelation Biosciences Inc   3.40 $ 6.499  Millions$ 1.914  Millions
Talphera Inc   3.35 $ 8.863  Millions$ 2.647  Millions
Nanoviricides inc   3.34 $ 3.958  Millions$ 1.184  Millions
Inozyme Pharma Inc   3.34 $ 113.087  Millions$ 33.898  Millions
Azitra Inc   3.31 $ 4.555  Millions$ 1.376  Millions

Date modified: 2025-04-08T16:46:24+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com